MedTrace Logo

Intestinal Microbiota, Tryptophan and Autism

NCT03751930 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2022-05-25

No results posted yet for this study

Summary

Autism Spectrum Disorder refers to complex neuro-developmental disorders that affect social communication and behavioral adaptation. Currently, the diagnosis of Autism Spectrum Disorder is based on a clinical examination that is performed classically during the first three years of life. The heterogeneity of the disorders occurring in autism make pathologies difficult to diagnose and manage.

The overall goal of this project is the identification of metabolic biomarkers based on clinical profile. The best characterization of physiopathological pathways will ultimately allow the identification of subgroups of subjects and facilitate the development of targeted therapeutics.

The proposed work aims to test the hypothesis of a disruption of tryptophan metabolism in Autism Spectrum Disorder via the gut microbiota.

Conditions

Interventions

OTHER

Samples

Urinary and faecal samples

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Patrick EMOND, MD · University Hospital, Tours

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-02
Primary Completion
2021-10-28
Completion
2021-10-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03751930 on ClinicalTrials.gov